Larotaxel

Overview

Larotaxel (XRP9881) is a taxane analogue with preclinical activity against taxane-resistant breast cancer . Larotaxel (XRP9881) exerts its cytotoxic effect by promoting tubulin assembly and stabilizing microtubules, ultimately leading to cell death by apoptosis . It presents the ability to cross the blood brain barrier and has a much lower affinity for P-glycoprotein 1 than Docetaxel.

Application

Products | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-125374
• CAS No.: 156294-36-9
• Molecular Formula: C45H53NO14
• Molecular Weight: 831.90
• Purity: 99.50%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (3.01 mM); Clear solution
• Availability: In-stock

Source

Original product source